With the advent of novel RANKL-scavenging antibodybased antiresorptive strategies (such as Denosumab-Pro-lia®, Amgen Inc.), it may further prove efficacious to target the RANK receptor directly with an antibody, in order to successfully antagonize receptor signaling and osteoclast function. However, neither the "scavenging" nor "antagonist" motives of those antiresorptive strategies focus on the targeted delivery of a given drug cargo (such as our anti-RANK mAb-conjugate design) which would function as a universal osteoclast targeting platform.